Claims
- 1. A method for killing tumor cells in a subject, comprising the step of administering to said subject a pharmaceutical composition comprising
- (A) a herpes simplex virus vector that is altered in (i) the .gamma.34.5 gene, and (ii) the ribonucleotide reductase gene; and
- (B) a pharmaceutically acceptable vehicle for said vector, such that said tumor cells are altered in situ by said vector, whereby said tumor cells are killed.
- 2. The method of claim 1, wherein said tumor cells are of a type selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, and medulloblastoma.
- 3. The method of claim 1, wherein said tumor cells are selected from the group consisting of melanoma cells, pancreatic cancer cells, prostate carcinoma cells, breast cancer cells, lung cancer cells, colon cancer cells, lymphoma cells, hepatoma cells and mesothelioma and epidermoid carcinoma cells.
- 4. A method for killing tumor cells in a subject, comprising the steps of administering to said subject a herpes simplex virus vector, wherein said vector comprises a tumor cell-specific promoter wherein said promoter controls expression of at least one viral protein necessary for viral replication and wherein said promoter is induced selectively or at a higher level in tumor cells than in normal cells.
- 5. The method of claim 4, wherein said promoter is selectively capable of expression in nervous system tumor cells.
- 6. The method of claim 4, wherein said tumor cells are of a type selected from the group consisting of glioblastoma, medulloblastoma, meningioma, neurofibrosarcoma, astrocytoma, oligodendroglioma, neurofibroma, ependymoma and Schwannoma.
- 7. The method of claim 4, wherein said tumor cells are of a type selected from the group consisting of melanoma, lung cancer, prostate carcinoma, breast cancer, pancreatic cancer, colon cancer, lymphoma, hepatoma and mesothelioma and epidermoid carcinoma.
- 8. The method of claim 4, wherein said vector is altered in the .gamma.34.5 gene and the ribonucleotide reductase gene.
- 9. The method of claim 1, wherein said pharmaceutical composition is introduced into the subject by injection, infusion, instillation or inhalation.
- 10. The method of claim 9, wherein said pharmaceutical composition is introduced into the subject by by a route selected from the group consisting of intratumor, intravenous, intraperitoneal, intramuscular, intratracheal, intravesicle, intraintestinal, intrarectal, intraoral, intraocular or intraarterial injection.
- 11. The method of claim 4, wherein said vector is introduced into the subject by injection, infusion, instillation or inhalation.
- 12. The method of claim 11, wherein said vector is introduced into the subject by intravenous injection.
Parent Case Info
This application is a continuation-in-part of Ser. No. 08/478,800 filed Jun. 7, 1995, abandoned, (which was a divisional application of Ser. No. 08/264,581 filed Jun. 23, 1994 U.S. Pat. No. 5,585,096) and the instant application is a continuation-in-part of Ser. No. 08/486,147 filed Jun. 7, 1995, U.S. Pat. No. 5,728,379 which was a continuation-in-part of Ser. No. 08/264,581 filed Jun. 23, 1994 U.S. Pat. No. 5,585,096.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5728379 |
Martuza et al. |
Mar 1998 |
|
Non-Patent Literature Citations (7)
Entry |
XO Breakefield et al. New Biologist 3:203-218, 1991. |
Toda, et al. "Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes simplexVirus 1", Human Gene Therapy 9:2177-2185 (Oct. 1998). |
Chahlavi, et al. "Replication-Competent Herpes simplexVirus Vector G207 and Cisplatin Combination Theapy for Head and Neck Squamous Cell Carcinoma", Neoplasia 1(2):162-169 (Jun. 2, 1999). |
Toda, et al. "Herpes simplexVirus as an in Situ Cancer Vaccine for the Induction of Spectrum Anti-Tumor Immunity", Human Gene Therapy 10:385-393 (Feb. 10, 1999). |
Nilaver, et al. "Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption", Proc. Natl. Acad. Sci. USA 92:9829-9833 (Oct. 1995). |
Neuwelt et al. "Delivery of ultraviolet-inactivated .sup.35 S-herpesvirus across an osmotically modified blood-brain barrier", J. Neurosurg 74:475-479 (Mar. 1991). |
Walker, et al. "Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating Herpes simplexvirus vector G207", Human Gene Therapy, pp. 1-28 (In Press Sep. 1999). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
264581 |
Jun 1994 |
|
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
478800 |
Jun 1995 |
|
Parent |
486147 |
Jun 1995 |
|
Parent |
264581 |
Jun 1994 |
|